Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application?
Radziewicz
Henry
H
Hanson
Holly L
HL
Ahmed
Rafi
R
Grakoui
Arash
A
D015703:Antigens, CD / Q000097:blood / Q000378:metabolism*; D000998:Antiviral Agents / Q000627:therapeutic use; D051017:Apoptosis Regulatory Proteins / Q000097:blood / Q000378:metabolism*; D060890:B7-H1 Antigen; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology*; D002451:Cell Compartmentation / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008099:Liver / Q000276:immunology / Q000821:virology*; D008213:Lymphocyte Activation; D010641:Phenotype; D061026:Programmed Cell Death 1 Receptor; D015398:Signal Transduction / Q000276:immunology
D015703:Antigens, CD; D000998:Antiviral Agents; D051017:Apoptosis Regulatory Proteins; D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor